Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHITEHALL TO MARKET UNIPATH's CLEARBLUE EASY ONE-STEP HOME PREGNANCY TEST

Executive Summary

WHITEHALL TO MARKET UNIPATH's CLEARBLUE EASY ONE-STEP HOME PREGNANCY TEST in the U.S. American Home Products' Whitehall division will support the second-generation OTC pregnancy kit with a national television and print campaign for consumers. A professional program also is planned. FDA cleared the product for marketing via a 510(k), the abbreviated application approval route for medical devices and in vitro diagnostics. Unipath, a subsidiary of Anglo/Dutch firm Unilever, introduced Clearblue Easy in the United Kingdom in June, Marketing Director John Bird told a Sept. 15 symposium sponsored by the Wilkerson Group in New York City. "We are now working to introduce that product in as many countries as possible in the next few months," he added. The test is designed to remove all need for user manipulation, Bird explained. To use the kit, the consumer holds a one-piece sampling device in the first morning urine stream, then replaces the cap and waits for three minutes. Results appear in two windows on the device. If a blue line appears in the first, larger window, it indicates pregnancy. A blue line will always appear in a second, smaller window to show that the test's integral control is working and that the test is successfully completed. Unipath's OTC diagnostics originally were sold in the U.S. by VLI Corporation, which was acquired by American Home in December 1987. VLI began selling Unipath's original Clearblue test in January 1987, followed by the Clearplan home ovulation test in September 1987. The new pregnancy test is being sold in Europe under the name Clearblue One Step. In the U.K., where Unipath holds about 50% of the home pregnancy testing market, the test is priced at about a 20% premium to competing products, Bird said. Whitehall said it is selling Clearblue Easy, which is available in packages of one or two tests, at a price "competitive" to existing products. Unipath was established in 1984 as the medical diagnostics subsidiary of Unilever. Located in Bedford, England, the company launched its first product, Clearblue, in 1985, and became the market leader within three months, Bird said. Unipath's OTC sales have grown from $ 1 mil. at the end of 1985 to $ 7 mil. by the end of 1987, Bird noted. While sales of Clearplan have been "disappointing," Bird said, growth in pregnancy product sales is expected to push 1988 OTC revenues to $ 11 mil.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel